This HTML5 document contains 82 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01416/identifier/national-drug-code-directory/
foafhttp://xmlns.com/foaf/0.1/
n26http://linked.opendata.cz/resource/mesh/concept/
n4http://linked.opendata.cz/resource/drugbank/company/
n10http://linked.opendata.cz/resource/drugbank/dosage/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01416/identifier/chemspider/
n8http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n23http://www.rxlist.com/cgi/generic/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01416/identifier/wikipedia/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01416/identifier/pharmgkb/
n11http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n25http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n24http://www.drugs.com/cdi/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01416/identifier/pubchem-compound/
n5http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/resource/drugbank/drug/DB01416/identifier/pubchem-substance/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01416/identifier/drugbank/
n21http://linked.opendata.cz/resource/atc/
n20http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01416
rdf:type
n3:Drug
n3:description
Cefpodoxime is an oral third generation cephalosporin antibiotic. It is active against most Gram positive and Gram negative bacteria. It is commonly used to treat acute otitis media, pharyngitis, and sinusitis. Cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime.
n3:dosage
n10:271B485D-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
2.09 to 2.84 hours
n3:indication
For the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms.
owl:sameAs
n8:DB01416 n11:DB01416
dcterms:title
Cefpodoxime
adms:identifier
n13:6335986 n14:46504897 n15:PA164746385 n16:0009-3617-01 n17:Cefpodoxime n18:4891496 n19:DB01416
n3:mechanismOfAction
Cefpodoxime is active against a wide spectrum of Gram-positive and Gram-negative bacteria. Cefpodoxime is stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and cephalosporins, due to their production of beta-lactamase, may be susceptible to cefpodoxime. Cefpodoxime is inactivated by certain extended spectrum beta-lactamases. The bactericidal activity of cefpodoxime results from its inhibition of cell wall synthesis. The active metabolite of cefpodoxime binds preferentially to penicillin binding protein 3, which inhibits production of peptidoglycan, the primary constituent of bacterial cell walls.
n3:packager
n4:271B4848-363D-11E5-9242-09173F13E4C5 n4:271B4849-363D-11E5-9242-09173F13E4C5 n4:271B4846-363D-11E5-9242-09173F13E4C5 n4:271B4847-363D-11E5-9242-09173F13E4C5 n4:271B484C-363D-11E5-9242-09173F13E4C5 n4:271B484D-363D-11E5-9242-09173F13E4C5 n4:271B484A-363D-11E5-9242-09173F13E4C5 n4:271B484B-363D-11E5-9242-09173F13E4C5 n4:271B4844-363D-11E5-9242-09173F13E4C5 n4:271B4845-363D-11E5-9242-09173F13E4C5 n4:271B4850-363D-11E5-9242-09173F13E4C5 n4:271B4851-363D-11E5-9242-09173F13E4C5 n4:271B484E-363D-11E5-9242-09173F13E4C5 n4:271B484F-363D-11E5-9242-09173F13E4C5 n4:271B4852-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Over the recommended dosing range (100 to 400 mg), approximately 29 to 33% of the administered cefpodoxime dose was excreted unchanged in the urine in 12 hours.
n3:synonym
Cefpodoxima Cefpodoximum
n3:foodInteraction
Take on empty stomach: 1 hour before or 2 hours after meals.
n3:proteinBinding
22 to 33% in serum and from 21 to 29% in plasma.
n3:synthesisReference
Yatendra Kumar, Neera Tewari, Ram Aryan, Bishwa Rai, Hashim Nizar, "Process for the preparation of cefpodoxime acid." U.S. Patent US20050020561, issued January 27, 2005.
n25:hasConcept
n26:M0150936
foaf:page
n23:vantin.htm n24:cefpodoxime.html
n3:IUPAC-Name
n5:271B4862-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B4868-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B4867-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B4864-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B4865-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B4866-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B4860-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B485E-363D-11E5-9242-09173F13E4C5 n5:271B4861-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B485F-363D-11E5-9242-09173F13E4C5
n20:hasATCCode
n21:J01DD13
n3:H-Bond-Acceptor-Count
n5:271B486E-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B486F-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B4869-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B486A-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B486C-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B486B-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B486D-363D-11E5-9242-09173F13E4C5
n3:absorption
Cefpodoxime proxetil is a prodrug that is absorbed from the gastrointestinal tract and de-esterified to its active metabolite, cefpodoxime. Following oral administration of 100 mg of cefpodoxime proxetil to fasting subjects, approximately 50% of the administered cefpodoxime dose was absorbed systemically.
n3:affectedOrganism
Enteric bacteria and other eubacteria
n3:casRegistryNumber
82619-04-3
n3:category
n3:containedIn
n9:271B4859-363D-11E5-9242-09173F13E4C5 n9:271B485A-363D-11E5-9242-09173F13E4C5 n9:271B4857-363D-11E5-9242-09173F13E4C5 n9:271B4858-363D-11E5-9242-09173F13E4C5 n9:271B485B-363D-11E5-9242-09173F13E4C5 n9:271B485C-363D-11E5-9242-09173F13E4C5 n9:271B4855-363D-11E5-9242-09173F13E4C5 n9:271B4856-363D-11E5-9242-09173F13E4C5 n9:271B4853-363D-11E5-9242-09173F13E4C5 n9:271B4854-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B4874-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B4876-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B4877-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B4873-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B4872-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B4875-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B4863-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B4870-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B4871-363D-11E5-9242-09173F13E4C5